Background-The ultrarapid outward current I Kur is a major repolarizing current in human atrium and a potential target for treating atrial arrhythmias. The effects of selective block of I Kur by low concentrations of 4-aminopyridine or the biphenyl derivative AVE 0118 were investigated on right atrial action potentials (APs) in trabeculae from patients in sinus rhythm (SR) or chronic atrial fibrillation (AF). Methods and Results-AP duration at 90% repolarization (APD 90 ) was shorter in AF than in SR (300Ϯ16 ms, nϭ6, versus 414Ϯ10 ms, nϭ15), whereas APD 20 was longer (35Ϯ9 ms in AF versus 5Ϯ2 ms in SR, PϽ0.05). 4-Aminopyridine (5 mol/L) elevated the plateau to more positive potentials from Ϫ21Ϯ3 to Ϫ6Ϯ3 mV in SR and 0Ϯ3 to ϩ12Ϯ3 mV in AF. 4-Aminopyridine reversibly shortened APD 90 from 414Ϯ10 to 350Ϯ10 ms in SR but prolonged APD 90 from 300Ϯ16 to 320Ϯ13 ms in AF. Similar results were obtained with AVE 0118 (6 mol/L).
T he cardiac repolarization process is regulated by several outward currents, of which the ultrarapid delayed rectifier potassium current (I Kur ) is thought to play a major role. This current is absent in the ventricles and hence represents a suitable target for selectively modulating action potentials (APs) in the atria. [1] [2] [3] The selective blocker of I Kur 4-aminopyridine in low micromolar concentrations is expected to prolong the AP duration (APD). However, experimental results in human atrial preparations from patients with sinus rhythm (SR) are inconsistent with shortening of APD in multicellular trabeculae 4 and prolongation of APD in isolated atrial myocytes. 1 Although block of I Kur and the subsequent prolongation of the APD are expected to be beneficial in chronic atrial fibrillation (AF), the experimental proof is still lacking. Furthermore, AF itself induces shortening of APD and effective refractory period, known as electrical remodeling, that is associated with changes in expression and activity of the involved ion channels. 5 Human I Kur was found to be reduced by Ϸ50%, whereas other groups reported no changes. 5 To predict the AP alterations associated with I Kur block during chronic AF, Courtemanche et al 2 simulated these changes in a model of human APs in AF and demonstrated that the reduction of I Kur was associated with prolongation of APD. However, this article only predicted the changes without experimental verification.
Here, we studied the effects of I Kur block with 4-aminopyridine and with the new I Kur blocker, the biphenyl derivative AVE 0118, on APs in trabeculae from SR and AF patients. The impact of I Kur block on other atrial currents was predicted by simulating APs in a modified Luo-Rudy model, and the predictions were tested experimentally by recording APs or force of contraction (F c ) in trabeculae or by measuring membrane currents in isolated atrial myocytes.
Methods

Human Tissue Samples and Patient Characteristics
The study was approved by the ethics committee of the Dresden University of Technology (No. EK790799). Each patient gave written, informed consent.
Right atrial appendages were obtained from 34 patients with SR and 18 patients with chronic AF (AF Ͼ6 months, Table 1 ). Significant differences between the 2 groups were found for underlying heart disease and pulmonary hypertension. AF patients more often received digitalis and diuretics, and ␤-blockers and lipidlowering drugs were prescribed more frequently in SR patients. Ventricular trabeculae (nϭ10) originated from left and right ventricles from 2 explanted end-stage failing hearts.
Electrophysiological Recordings
Atrial APs were recorded with conventional intracellular microelectrodes in right atrial trabeculae (microelectrode tip resistance, 10 to 25 M⍀; 1-ms stimulus, 25% above threshold intensity). The bath solution contained (in mmol/L): NaCl 127, KCl 4.5, MgCl 2 1.5, CaCl 2 1.8, glucose 10, NaHCO 3 22, and NaH 2 PO 4 0.42, equilibrated with O 2 /CO 2 (95:5) at 35Ϯ2°C, pH 7.4. A computer-aided system (developed at the University of Szeged, Hungary) was used for generating stimuli and data acquisition of various AP parameters. After equilibration for 1 hour, control APs were recorded for 20 minutes before 4-aminopyridine or AVE 0118 was cumulatively added, with 20 minutes of recording between concentration increments.
Human myocytes were isolated from atrial appendages as previously described. 6 I Ca,L and I K1 were measured with conventional voltage-clamp technique as previously described. 6, 7 Mean cell capacitance was 101Ϯ6.5 pF (nϭ29).
Measurement of F c
Pairs of right atrial or ventricular trabeculae were mounted in organ baths filled with 50 mL of buffer (composition in mmol/L: NaCl 126.7, KCl 5.4, CaCl 2 1.8, MgCl 2 1.05, NaHCO 3 22.0, NaH 2 PO 4 0.42, EDTA 0.04, and glucose 5.0, equilibrated with O 2 /CO 2 [95:5] at 37°C, pH 7.4). 8 The bath solution contained 200 nmol/L (Ϫ)-propranolol to exclude effects mediated through ␤-adrenoceptors. The preparations were paced (0.5 Hz, 5-ms stimulus, 10% above threshold intensity) and were stretched to 80% of the length associated with maximum developed force. After an equilibration period of 30 minutes, the effects of 4-aminopyridine or AVE 0118 on F c were determined by cumulatively increasing concentrations every 20 minutes.
Action Potential Simulations
For simulating the shapes of human atrial APs, we modified mathematical models described in the literature. 9 -11 The incorporated membrane currents and transporters and factors controlling intracellular ion concentrations are listed in the Appendix (see online-only Data Supplement), which also contains specific kinetic parameters, constants of ion currents, and the equations used for current calculations. Maximum current conductances of I Ca,L , I to,f , I Kur , I K1 , and I NaCaX were adapted to simulate the characteristic AP shapes. For AP simulation in chronic AF, original current data were taken from the literature and, when not available, amplitudes were extrapolated from changes in channel expression.
As an approximation, APs were assumed to be spatially uniform, ie, conduction within the preparation was neglected. Changes of membrane potential were calculated for space-clamp conditions as follows: d(V m )/dt ϭ Ϫ(I ion,total ϩI stim )/C m , with I ion,total ϭ I Na ϩI Ca,T ϩ I Ca,L ϩI to,f ϩI Kur ϩI Kr ϩI Ks ϩI K1 ϩI K,Ach ϩI K,Ca ϩI b,Na ϩI b,Ca ϩI b,Cl ϩ I Na,Kpump ϩ I NaCaE and I stim ϭ stimulus current of Ϫ90 A/F applied 0.5 ms at beginning of each cycle, and C m ϭ membrane capacitance (specific C m assumed to be 1 F/cm 2 ).
Numerical integration of d(V m )/dt was performed according to a modified Euler method suggested by Rush and Larsen. 12 The length of the time steps was varied between 0.02 and 20 ms, depending on the extent of resultant voltage changes. Momentary values of gating variables were calculated from analytical solution of the related first-order differential equations 9 -11,13 
Simulated APs, currents, and ionic concentrations were allowed to stabilize for at least 200 cycles. The model was implemented in Turbo Pascal 6.0. For further details of the model, see Appendix.
Statistical Analysis
Differences between continuous data were compared by unpaired Student t test or 1-way ANOVA. Frequency data were analyzed with 2 statistics. Data are meanϮSEM. A value of PϽ0.05 was considered statistically significant.
Results
Effect of 4-Aminopyridine on AP Configuration in SR and AF
Resting membrane potentials were Ϫ75Ϯ1 mV in SR (nϭ15) and significantly more negative in AF (Ϫ80Ϯ3 mV, nϭ6, PϽ0.05). In accordance with our previous results, 14 APD at 20% of repolarization (APD 20 ) was shorter in SR (5Ϯ2 ms) than in AF (35Ϯ9 ms, PϽ0.05), whereas APD 90 was longer in SR (414Ϯ10 ms) compared with AF (300Ϯ16 ms, PϽ0.05). In the presence of 4-aminopyridine (5 mol/L), the potentials of the notch and dome (SR) and of the plateau shoulder (AF) were shifted to more positive values, leading to a significant increase in APD 20 from 5Ϯ2 to 12Ϯ5 ms in SR (Pϭ0.05) and from 35Ϯ9 to 78Ϯ5 ms in AF (Pϭ0.002, Figure 1 , A and B). The final repolarization phase was accelerated in both groups; however, APD 90 was shortened from 414Ϯ10 to 350Ϯ10 ms in SR (PϽ0.0001) but was prolonged from 300Ϯ16 to 320Ϯ13 ms in AF (Pϭ0.006; Figure 1 , C and D), suggesting that the directions of APD 90 changes are different in SR and AF. The effects of 4-aminopyridine were reversible on washout.
In SR preparations, the mean notch potential, ie, the minimum potential after the initial rapid repolarization phase, was shifted by 4-aminopyridine (5 mol/L) from Ϫ32Ϯ4 to Ϫ22Ϯ5 mV (PϽ0.003), and the mean dome potential, ie, the most positive plateau potential before final repolarization, was shifted from Ϫ28Ϯ4 to Ϫ13Ϯ6 mV (Pϭ0.001). Because APs in AF did not exhibit the typical notch as in SR, we introduced the parameter "plateau potential" for analysis of changes in this potential range. Plateau potential is defined as the mean amplitude within the time window of 20 to 80 ms after the upstroke of the AP (Figure 1, A and B) . In SR, the plateau potential was shifted by 4-aminopyridine (5 mol/L) from Ϫ21Ϯ3 to Ϫ6Ϯ3 mV (PϽ0.0001, Figure 1E ). In AF, the plateau potential was more positive (0Ϯ3 mV, Pϭ0.0001 versus SR) and was shifted by 4-aminopyridine to ϩ12Ϯ3 mV (Pϭ0.0012, Figure 1F ).
The effect of 4-aminopyridine on the shift in notch-anddome potentials was concentration-dependent (0.3 to 100 mol/L, Figure 2 , A and B). In SR, the notch potential became less negative and shifted from Ϫ23Ϯ2 to Ϫ4Ϯ2 mV with 100 mol/L 4-aminopyridine ( Figure 2 , A and C, nϭ5, PϽ0.001), and the respective dome potential was changed from Ϫ18Ϯ1 to 0Ϯ2 mV (PϽ0.001). Nonlinear curve fitting resulted in EC 50 values of 15 mol/L 4-aminopyridine for elevation of notch potential and 14 mol/L for elevation of dome potential ( Figure 2C ). In AF, the effect of 4-aminopyridine on the plateau potential was also concentrationdependent, with an EC 50 value of 28 mol/L in 1 experiment (Figure 2 , B and D).
Model Simulations of APs in SR and AF: Block of I Kur
Inserting experimentally estimated parameters into the mathematical model of human atrial APs (see Appendix) provided the spike-and-dome shape typical for tissue from SR patients (compare Figures 1A and 3 ). Selective inhibition of I Kur by 4-aminopyridine was simulated by setting the current to 20% of its regular value in SR (see Table 2 ). The model reproduced the observed shifts of notch-and-dome potentials to more positive values ( Figure 3 ) and shortened APD 90 . Block of I Kur induced a series of indirect effects on other currents because of their voltage and time dependence during the course of a free-running action potential. The model predicted peak I Ca,L to increase by 37% at the elevated plateau potential ( Figure 3 ) and increases in the outward potassium currents I Kr and I Ks by 80% and 50%, respectively.
The characteristic triangular shape of APs in AF was reproduced by setting conductances of I K1 , I Ca,L , I to,f , I Kur , and I NaCaX to values of reported ion current densities or channel expression ( Figures 1B and 3 ; see Reference 5 and Table 2 ). The effect of 4-aminopyridine was simulated by setting the maximum conductance of I Kur to 20% of the AF control value and computing membrane currents in the course of the resulting AP. The simulation produced a shift of the plateau potential and an overall prolongation of APD 20 and APD 90 (Figure 3 ). The accompanying indirect changes of other currents were qualitatively similar to those in SR but were substantially smaller in size.
Experimental Verification of Model Predictions (I Ca,L , I Kr )
The model predicted an increase of I Ca,L by block of I Kur . 4-Aminopyridine did not modulate I Ca,L in atrial myocytes (peak current density during clamp steps from Ϫ80 to ϩ10 mV: 5.5Ϯ1.3 pA/pF before and 5.1Ϯ1.0 pA/pF after 100 mol/L 4-aminopyridine, nϭ8 cells from 6 SR patients; PϭNS). Similar results, although at lower basal I Ca,L , were obtained in atrial myocytes from AF patients (data not shown). 4-Aminopyridine (100 mol/L) had no effect on I K1 (data not shown).
To test for indirect effects of block of I Kur on Ca 2ϩ entry via I Ca,L , we measured F c as an indirect indicator of I Ca,L activity ( Figure 4A ). In SR trabeculae, 4-aminopyridine (100 mol/L) enhanced F c from 4.5Ϯ0.7 to 7.3Ϯ1.1 mN (nϭ8/6 [trabeculae/patients], PϽ0.05). The EC 50 for 4-aminopyridine obtained by curve fitting was 52 mol/L ( Figure 4B ). With 1 mmol/L 4-aminopyridine, F c increased maximally (8.8Ϯ1.3 mN), corresponding to 58Ϯ3% of the F c developed by 8 mmol/L CaCl 2 (14.9Ϯ1.6 mN). As expected, basal F c was lower (1.3Ϯ0.4 mN, nϭ9/5, PϽ0.001) and the effect of 4-aminopyridine on F c was smaller in AF than in SR. F c increased at 1 mmol/L 4-aminopyridine to 2.9Ϯ0.9 mN, corresponding to 28Ϯ8% of that obtained by 8 mmol/L CaCl 2 (10.9Ϯ1.6 mN, PϭNS versus SR). The EC 50 value was 36 mol/L. The positive inotropic effects were not affected by (Ϫ)-propranolol and hence were independent of enhanced neurotransmitter release. 8 If the effect of 4-aminopyridine on F c was a result of the blockade of I Kur , it should be absent in ventricular preparations, in which I Kur cannot be measured. 15 Indeed, 4-aminopyridine (0.3 mol/L to 1 mmol/L) did not affect F c in ventricular trabeculae (Figure 4 , C and D), excluding a direct effect of 4-aminopyridine on Ca 2ϩ release or contractile machinery.
According to the model prediction in SR, the shortening of APD 90 by block of I Kur is expected to be induced by an increase in I Kr . Block of I Kr with E-4031 (1 mol/L) prolonged APD 90 , although the effect did not reach the level of statistical significance (Pϭ0.3661, nϭ5); Figure 5 , A and C). In the presence of E-4031, 4-aminopyridine (25 mol/L) no longer shortened but rather prolonged APD 90 from 412Ϯ43 to 483Ϯ33 ms (nϭ5, Pϭ0.2217; versus control, Pϭ0.0249) and significantly elevated the notch and plateau potentials from Ϫ30Ϯ2 to Ϫ19Ϯ3 mV (nϭ5, PϽ0.05) and from Ϫ27Ϯ2 to Ϫ14Ϯ3 mV (nϭ5, PϽ0.001), respectively. These effects were reproduced in the model simulation by reducing the conductance of I Kr by 95% and that of I Kur by 90% ( Figure 5B ).
Effect of the I Kur Blocker AVE 0118 on AP in SR and AF
The effects of I Kur inhibition were verified with the new I Kur blocker AVE 0118 (6 mol/L). AVE 0118 revealed the typical changes in AP shape as found with low concentrations of 4-aminopyridine (5 mol/L), ie, elevation of the plateau potential from Ϫ16.3Ϯ4.1 to Ϫ6.7Ϯ4.2 mV (nϭ9, PϽ0.01) in the presence of 6 mol/L AVE 0118, and shortening of ADP 90 from 343Ϯ14 to 328Ϯ17 ms (Pϭ0.066) in SR. In AF, the plateau amplitude increased from Ϫ2.4Ϯ3.6 to 8.8Ϯ3.6 mV (nϭ6, PϽ0.001), and APD 90 increased from 260Ϯ14 to 280Ϯ13 ms (PϽ0.05; Figure 6 ). 
Discussion
The concept of block of I Kur as a therapeutic target in AF is widely accepted, 3 despite inconsistent experimental and theoretical evidence for changes in APD. Here, we report that selective block of I Kur shortens APD of human atrial trabeculae from SR but prolongs APD in AF. Changes in APD in SR and AF were consistent with secondary current changes as predicted by a modified Luo-Rudy model and were verified experimentally.
Effects of Block of I Kur on Shapes of Atrial APs in SR and AF
In low concentrations, 4-aminopyridine is a selective blocker of I Kur . In earlier work, we found that 4-aminopyridine blocks I Kur and I to,f in human atrial myocytes with IC 50 values of 8 mol/L and 1 mmol/L, respectively. 15 Similar values were published by others (ie, 49 mol/L for I Kur and 1.9 mmol/L for I to,f ). 1 Block of repolarizing outward current is expected to prolong APD; however, we observed shortening in SR preparations instead. In the literature, shortening, 4 prolongation, 1 and even no effect at all have been reported. 2 How can these inconsistencies be reconciled? The shape of the cardiac AP is the result of the balanced activity of several ion currents. Provided that 4-aminopyridine at the concentrations used is in fact selective for I Kur block, APD shortening in SR must be associated with alterations in additional currents. In this context, the pronounced elevation of the action potential plateau may provide an important clue because enhanced amplitude of I Ca,L at more positive potentials could activate repolarizing outward currents that would shorten APD. 4 In AF, block of I Kur resulted in the expected APD prolongation. The characteristic triangular AP shape in AF compared with the spike-and-dome configuration in SR is a result of electrical remodeling that comprises changes in several ion Table  2 . Simulated AP under control conditions (solid line, g max of I Kur is 100% of AF and 48% of g max in SR) and after reducing I Kur to 20% (dashed line, g max of I Kur is 9.6% of g max in SR). Reducing conductances. The densities of I Ca,L and I to,f are reduced by Ϸ70% 16, 17 and Ϸ60%, 16, 18, 19 respectively, and inward rectifier I K1 is increased by Ϸ100%. 14, 16, 18, 20 From these considerations, it follows that selective block of I Kur (or any other current) will perturb the balance of ion channel activation differently in AF and SR and may result in different patterns of secondary effects.
Computer Simulations: Indirect Effects of 4-Aminopyridine on I Ca,L
To predict individual current changes secondary to selective block of I Kur , we used a computer model of AP simulation. For this purpose, ion conductances in the Luo-Rudy model 9 were set to the experimentally observed values reported recently for human AF. The model simulated the characteristic AP shapes. For selective block of I Kur in SR APs, the model produced a more pronounced spike-and-dome configuration. The shift of the plateau to more positive potentials was associated with enhanced I Ca,L activation in the model (although 4-aminopyridine had no direct effects on I Ca,L ) and is expected to increase systolic Ca 2ϩ influx during a freerunning AP. Indeed, 4-aminopyridine significantly increased F c in atrial trabeculae in a concentration-dependent manner (see Figure 4 ) in SR and AF, respectively. Although the positive inotropic effect was much smaller in AF, it is considered to be clinically interesting, because atrial contractility is already impaired in AF 21 and all other drugs currently used in the treatment of AF, eg, ␤-adrenoceptor blockers or calcium channel blockers, have a negative inotropic effect.
Computer Simulations: Indirect Effects of 4-Aminopyridine on I Kr
Secondary enhancement of outward currents as an explanation for APD shortening in SR by block of I Kur was also predicted by the model. As the likely candidates, the model identified I Kr and I Ks . Because of its slow activation kinetics, I Ks will not play a major role in the course of the short atrial APs. Conversely, the impact of I Kr was examined experimentally: pharmacological block of I Kr in trabeculae from SR unmasks the APD-prolonging effect of I Kur block (see Figure  5 ). Therefore, we speculate that 4-aminopyridine prolongs APD in atrial myocytes, because I Kr may be absent because of the enzymatic isolation procedure, as was shown for canine atrial myocytes. 22 The model simulation of the human atrial SR AP reproduces the experimentally observed APD shortening that is induced by I Kur block. However, this experimental finding is reproduced only when I Kr is set to sufficiently high values ( Table 2) . If low values are used (see, for instance, Nygren et al 23 ), APD either is prolonged 23 or remains unaffected. 2 Although the large conductance of I Kr assumed in our model was not proved with current measurements, the APDprolonging effect of I Kr block by E-4031 ( Figure 5 ) points to a prominent role of this current in atrial repolarization, supported also by current measurements of I Kr in human atrium. 24 In the presence of I Kr block, I Kur inhibition further prolonged APD. We therefore assume that in multicellular trabeculae, I Kr was fully available for repolarization. In conscious dogs, the I Kr blocker ibutilide prolonged atrial monophasic APs and effective refractory period, 25 providing evidence for a prominent I Kr contribution.
Because I Ca,L is reduced in AF, block of I Kur cannot produce much indirect increase in I Ca,L , and therefore the plateau is only slightly elevated. Because of enhanced I K1 in AF, rapid and strong induction of the repolarization process abbreviates the time window for activation of I Kr and thus reduces its repolarizing potency. All interacting factors together will produce an AP-prolonging effect of I Kur block, which possibly represents the antiarrhythmic potency of putative I Kur blockers.
Study Limitations
The majority of patients donating tissue samples suffered from coronary artery disease. Therefore, AP measurements from SR trabeculae may not be considered to be fully representative of APs from trabeculae of a healthy population. In addition, the patients' medications may have additional effects. The large variability in action potential shapes may represent this inhomogeneity of the material.
Early repolarization is controlled not only by I Kur but also by I to,f . Although low concentrations of 4-aminopyridine are selective for block of I Kur , a contribution of I to,f block cannot be excluded at larger concentrations. In the absence of selective blockers for I to,f , model simulations are useful for estimating the consequences of I to,f block on atrial AP. Like I Kur block, reduced basal conductance of I to,f shifted the notch potential to more positive values and abbreviated APD 90 in Values are in mS/F except as noted. For simulations of AF action potentials, channel conductances were adapted to correspond to the reported changes in current density or were extrapolated from changes in mRNA and protein levels. 5 SR and only slightly prolonged APD 90 in AF. In contrast to I Kur block, selective block of I to,f did not elevate the dome potential or enhance the spike-and-dome configuration (data not shown). The rapid I to,f inactivation most likely limits indirect enhancement of I Kr if I to,f is blocked.
Conclusions
We hypothesize that I Kur is a major determinant in controlling action potential shape and therefore also contractility in the human atrium. The antiarrhythmic potency of I Kur inhibitors is determined largely by the level of electrical remodeling of the diseased atrium. Although the antiarrhythmic effectiveness of I Kr blockers is significantly attenuated in chronic AF, 26 selective I Kur blockers may be more potent in prolonging atrial refractory period in chronic AF than in SR and may therefore be more efficient in terminating AF than in maintaining SR.
